DMAC
NASD DiaMedica Therapeutics Inc.$7.82 ↑ +0.00 (+0.00%) Trading Up from the previous close of $7.82, $0.39 below the day’s high of $8.21
- YTD change
- -1.76%
- vs 20-day SMA
- +0.46%
- vs 200-day SMA
- +10.28%
Price ranges
Price & Performance
+1.52 (+24.13%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 28.1% away from all-time highs of $10.88
- DMAC is down 2% since the beginning of the year
- DMAC is up 11% over the past 12 months
- DMAC is up 19% over the past 1 month
- 15% of all DMAC investors are betting against DMAC
DMAC reads neutral: price sits above both the 20- and 200-day averages, the 12-month move is +10.8%.
- Previous minute
- +$0.00
- Last hour
- +$0.12
- Last 5 days
- -7.13%
- vs 8-day SMA
- -4.72%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
DiaMedica Therapeutics, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of novel recombinant proteins. It develops the DM199 product candidate, which focuses on acute ischemic stroke (AIS) and chronic kidney disease (CKD). The company was founded by Wayne Lautt on January 21, 2000 and is headquartered in Minneapolis, MN.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
